 | | Vol. 12.31 – 20 August, 2021 |
| |
|
|
| Scientists showed that BAZ2A was required for prostate cancer (PCa) cells with a cancer stem-like state. BAZ2A genomic occupancy in PCa cells coincided with H3K14ac-enriched chromatin regions.
[EMBO Reports] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified 6-phosphogluoconate dehydrogenase as an androgen-regulated gene that was upregulated in prostate cancer.
[eLife] |
|
|
|
| Researchers explored the mechanism involved in metformin-mediated inhibition of AR-negative prostate cancer.
[Cancer Cell International] |
|
|
|
| Investigators reported Mangiferin (MGF) functionalized gold nanoparticulate agent and its immunomodulatory characteristics in treating prostate cancer.
[Scientific Reports] |
|
|
|
| Scientists showed that methylseleninic acid substantially attenuated cisplatin-induced PD-L1 expression via inhibiting protein kinase B phosphorylation, thereby potentiated cisplatin cytotoxicity in prostate and lung cancer cell models.
[Molecular Carcinogenesis] |
|
|
|
| The co-expression network of HN1 from the TCGA PRAD dataset indicated the putative role of HN1 in centrosome-related processes in the context of prostate cancer. HN1 expression was low in normal RWPE-1 cells as compared to cancerous androgen-responsive LNCaP and androgen insensitive PC-3 cells.
[Cell Cycle] |
|
|
|
| Compared with tumor-adjacent normal tissues, death-associated protein kinase 1 (DAPK1) expression was reduced in prostate cancer cell lines with respect to that in normal prostate cells.
[Stem Cells and Development] |
|
|
|
| Researchers generated two novel cell line models which were derived by passaging LAPC4 and VCaP cells in vivo and in vitro under castrate conditions.
[Prostate] |
|
|
|
| Scientists characterized the mechanisms behind prostate CSC-platelet interaction. Fluorescence Activated Cell Sorting was utilized to separate DU145 and PC3 prostate cancer cells into CD133+/CD44+, CD133+/CD44–, CD44+/CD133–, and CD133–/CD44– subpopulations and to measure their CXCR4 surface expression.
[Thrombosis Research] |
|
|
|
|
| Scientists summarize the impact of PCAT6 in the development of diverse types of cancers, based on the results of functional studies in cell lines, experiments in xenograft models of cancers and expression studies in samples obtained from human subjects.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| Seagen, Inc. and RemeGen Co., Ltd. announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate.
[Seagen, Inc.] |
|
|
|
|
| October 14, 2021
Wädenswil, Switzerland |
|
|
|
|
|
| | Dana-Farber Cancer Institute- Boston, Massachusetts, United States |
|
|
|
| University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
| | | Cornell University – New York City, New York, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
